Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Loisel, Séverine ^a   André, Pierre Alain ^b   Golay, Josee ^c   Buchegger, Franz ^b,d   Kadouche, Jean ^e   Cérutti, Martine ^f   Bologna, Luca ^c   Kosinski, Marek ^b,g   Viertl, David ^b   Delaloye, Angelika B ^b   Berthou, Christian ^a   Mach, Jean Pierre ^g   Boumsell, Laurence ^h  

^a UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c OSPEDALI RIUNITI   (Italy)

^d Universite de Brest   (France)

^e MAT Ltd   (France)

^f Centre National de La Recherche Scientifique (CNRS) UPS 3044   (France)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

^h INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; CD71 ANTIGEN; HLA DR ANTIGEN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD5; MONOCLONAL ANTIBODY CD71; MONOCLONAL ANTIBODY HLA DR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CHRONIC LYMPHOCYTIC LEUKEMIA; B LYMPHOCYTE; B LYMPHOCYTE LEUKEMIA; BINDING AFFINITY; CELL AGGREGATION; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEUKEMIA; LYSIS; MOUSE; NONHUMAN; PHAGOCYTOSIS; PURIFICATION; SURVIVAL RATE; TREATMENT RESPONSE; ANIMAL; B CELL LEUKEMIA; COMPLEMENT ACTIVATION; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; LYMPHOMA; MACROPHAGE; MOUSE MUTANT; PATHOPHYSIOLOGY; PROTEIN BINDING; SURVIVAL; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; HUMANS; IODINE RADIOISOTOPES; LEUKEMIA, B-CELL; LYMPHOMA; MACROPHAGES; MICE; MICE, SCID; PHAGOCYTOSIS; PROTEIN BINDING; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955124560     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-42     Document Type: Article

References (45)

1. Boumsell L, Bernard A, Lepage V, Degos L, Lemerle J, Dausset J. Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T cells. Eur J Immunol 1978, 8:900-904. 10.1002/eji.1830081214, 83236.
2. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ, Sison CP, Allen SL, Kolitz J, Schulman P, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002, 99:4087-4093. 10.1182/blood.V99.11.4087, 12010811.
3. Friedlein G, El Hage F, Vergnon I, Richon C, Saulnier P, Lecluse Y, Caignard A, Boumsell L, Bismuth G, Chouaib S, Mami-Chouaib F. Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J Immunol 2007, 178:6821-6827.
4. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 2002, 100:4537-4543. 10.1182/blood-2002-05-1525, 12393419.
5. Dillman RO, Shawler DL, Dillman JB, Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984, 2:881-891.
6. Miller RA, Oseroff AR, Stratte PT, Levy R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 1983, 62:988-995.
7. Hertler AA, Schlossman DM, Borowitz MJ, Laurent G, Jansen FK, Schmidt C, Frankel AE. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J Biol Response Mod 1988, 7:97-113.
8. Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, Neumann RD, Boland C, Perentesis P, Brown MR, et al. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res 1998, 4:2691-2700.
9. Cioca DP, Kitano K. Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia. Leukemia 2002, 16:335-343. 10.1038/sj.leu.2402393, 11896536.
10. Pers JO, Berthou C, Porakishvili N, Burdjanadze M, Le Calvez G, Abgrall JF, Lydyard PM, Youinou P, Jamin C. CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia. Leukemia 2002, 16:44-52. 10.1038/sj.leu.2402327, 11840262.
11. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006, 121:144-158. 10.1016/j.clim.2006.06.010, 16904380.
12. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983, 36:539-545. 10.1136/jcp.36.5.539, 498283, 6302135.
13. Das Gupta A, Shah VI. Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Hematol Pathol 1990, 4:37-41.
14. Taetle R, Honeysett JM, Trowbridge I. Effects of anti-transferrin receptor antibodies on growth of normal and malignant myeloid cells. Int J Cancer 1983, 32:343-349. 10.1002/ijc.2910320314, 6309680.
15. Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht TT, Kornfeld S, Taetle R. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Clin Cancer Res 1995, 1:1259-1265.
16. Qing Y, Shuo W, Zhihua W, Huifen Z, Ping L, Lijiang L, Xiaorong Z, Liming C, Daiwen X, Yu H, et al. The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor. Cancer Immunol Immunother 2006, 55:1111-1121. 10.1007/s00262-005-0105-7, 16341531.
17. Kaufman JF, Auffray C, Korman AJ, Shackelford DA, Strominger J. The class II molecules of the human and murine major histocompatibility complex. Cell 1984, 36:1-13. 10.1016/0092-8674(84)90068-0, 6198089.
18. Newell MK, VanderWall J, Beard KS, Freed JH. Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc Natl Acad Sci USA 1993, 90:10459-10463. 10.1073/pnas.90.22.10459, 47796, 8248132.
19. Yoshino T, Cao L, Nishiuchi R, Matsuo Y, Yamadori I, Kondo E, Teramoto N, Hayashi K, Takahashi K, Kamikawaji N, et al. Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO-1)-mediated apoptosis. Eur J Immunol 1995, 25:2190-2194. 10.1002/eji.1830250811, 7545111.
20. Golay J, Bologna L, André PA, Buchegger F, Mach JP, Boumsell L, Introna M. Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. Blood 2010, 116:3372-3. 10.1182/blood-2010-06-289736, 21030571.
21. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer 1997, 80:2706-2711. 10.1002/(SICI)1097-0142(19971215)80:12+<2706::AID-CNCR49>3.0.CO;2-D, 9406728.
22. Brown KS, Levitt DJ, Shannon M, Link BK. Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma. Clin Lymphoma 2001, 2:188-190. 10.3816/CLM.2001.n.026, 11779298.
23. Dunleavy K, White T, Grant N, Shovlin M, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Marti G, Janik J, Wilson WH. Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia. J Clin Oncol (Meeting Abstracts) 2005, 23:6607.
24. Kansas GS, Tedder TF. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J Immunol 1991, 147:4094-4102.
25. Mourad W, Geha RS, Chatila T. Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule 1-dependent cell adhesion. J Exp Med 1990, 172:1513-1516. 10.1084/jem.172.5.1513, 2188675, 2230655.
26. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004, 199:1659-1669. 10.1084/jem.20040119, 2212805, 15210744.
27. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009, 182:4415-4422. 10.4049/jimmunol.0713732, 19299742.
28. Introna M, Golay J. Complement in antibody therapy: friend or foe?. Blood 2009, 114:5247-5248. 10.1182/blood-2009-10-249532, 20018922.
29. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446. 10.1038/74704, 10742152.
30. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758. 10.1182/blood.V99.3.754, 11806974.
31. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796. 10.1200/JCO.2007.14.8957, 18347005.
32. Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pelegrin A, Azria D. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol 21:98-103. 10.1093/annonc/mdp496, 19889608.
33. Bondada S, Bikah G, Robertson DA, Sen G. Role of CD5 in growth regulation of B-1 cells. Curr Top Microbiol Immunol 2000, 252:141-149.
34. Folkman J. Angiogenesis. Annu Rev Med 2006, 57:1-18. 10.1146/annurev.med.57.121304.131306, 16409133.
35. Dechant M, Bruenke J, Valerius T. HLA class II antibodies in the treatment of hematologic malignancies. Semin Oncol 2003, 30:465-475. 10.1016/S0093-7754(03)00252-5, 12939715.
36. Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, Coleman M, Goldenberg DM. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008, 113:2714-2723. 10.1002/cncr.23890, 18853418.
37. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003, 101:3413-3415. 10.1182/blood-2002-07-1952, 12522009.
38. Nabhan C, Patton D, Gordon LI, Riley MB, Kuzel T, Tallman MS, Rosen ST. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004, 45:2269-2273. 10.1080/10428190412331286096, 15512816.
39. Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE, Hicklin DJ. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006, 12:2197-2207. 10.1158/1078-0432.CCR-05-1682, 16609035.
40. Larbouret C, Robert B, Navarro-Teulon I, Thezenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pelegrin A, Azria D. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 2007, 13:3356-3362. 10.1158/1078-0432.CCR-06-2302, 17545543.
41. Loisel S, Ster KL, Quintin-Roue I, Pers JO, Bordron A, Youinou P, Berthou C. Establishment of a novel human B-CLL-like xenograft model in nude mouse. Leuk Res 2005, 29:1347-1352. 10.1016/j.leukres.2005.04.017, 15896841.
42. Rickers A, Peters N, Badock V, Beyaert R, Vandenabeele P, Dorken B, Bommert K. Cleavage of transcription factor SP1 by caspases during anti-IgM-induced B-cell apoptosis. Eur J Biochem 1999, 261:269-274. 10.1046/j.1432-1327.1999.00273.x, 10103059.
43. Schaffland AO, Buchegger F, Kosinski M, Antonescu C, Paschoud C, Grannavel C, Pellikka R, Delaloye AB. 131I-rituximab: relationship between immunoreactivity and specific activity. J Nucl Med 2004, 45:1784-1790.
44. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984, 72:77-89. 10.1016/0022-1759(84)90435-6, 6086763.
45. Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, van Rooijen N, Vago L, Introna M. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006, 91:176-183.